Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jaiveer, P.
Right arrow Articles by Patel, V.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Alphabet strategy — a tool to achieve clinical trial standards in routine practice?

Pachaiappan Jaiveer

Jaiveer Saraswathy

James D Lee

John Morrissey

Vinod Patel

Diabetes and Endocrinology Centre, George Eliot Hospital NHS Trust, College Street, Nuneaton, CV10 7DJ, UK, vinod.patel{at}geh.nhs.uk

The Steno-2 study and UKPDS showed that targeted intensified intervention on modifiable cardiovascular risk factors in patients with type 2 diabetes reduces morbidity and mortality. The Alphabet POEM strategy (Practice Of Evidence-based Medicine) assessed the effect of systematic application of the Alphabet Strategy to care of patients with type 2 diabetes. In comparison to the Steno-2 intensive cohort, Alphabet POEM fared similarly with regard to diastolic blood pressure (BP), HbA1C, aspirin and angiotensin-converting enzyme (ACE) inhibitor use, but less well with respect to systolic BP, total cholesterol and use of statins. Alphabet POEM achieved better systolic and diastolic BP than UKPDS but glycaemic control was significantly worse. The standards achieved in the Steno-2 study and UKPDS are in principle, at least, partially achievable in a district general hospital in the UK, but fully achieving them in practice will probably need a radical restructuring, and greater provision of resources.

Key Words: Alphabet strategy • Framingham heart risk. Key words: type 2 diabetes • Steno-2 study • UKPDS

References

  • Bhopal RS, Unwin N., White M. et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ 1999;319:215-20.[Abstract/Free Full Text]
  • King H., Aubert RE, Herman WH Global burden of diabetes 19952025: prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414-31.[Abstract]
  • Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association Cohort Study, I: all-cause mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999;16:459-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999;16:466-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rosengren A., Welin L., Tsipogianni A., Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 1989;299:1127-31.[Abstract/Free Full Text]
  • Currie CJ, Kraus D., Morgan CL, Gill L., Stott NC, Peters JR NHS acute sector expenditure for diabetes: the present, future, and excess in-patient cost of care. Diabet Med 1997;14:686-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • National Service Framework for Diabetes: Delivery Strategy. Department of Health, 2002.
  • Levy JC UKPDS Odyssey. Br J Diabetes Vasc Dis 2001;1:14-21.[Abstract/Free Full Text]
  • Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial: HOT study Group. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Department of Health. National Service Framework for Coronary Artery Disease. Modern Standards and Service Models London: Department of Health 2000.
  • Gaede P., Vedel P., Larsen N., Jensen GV, Parving HH, Pedersen O. Multifactorial Intervention and cardiovascular disease in patients with type 2 Diabetes. N Engl J Med 2003;348:383-93.[Abstract/Free Full Text]
  • Gaede P., Vedel P., Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the steno type 2 randomised study. Lancet 1999;353:617-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Patel V., Morrissey J. The Alphabet Strategy: the ABC of reducing diabetes complications. Br J Diabetes Vasc Dis 2002;2:58-9.[Abstract/Free Full Text]
  • US Preventive services Task Force: Counseling to prevent tobacco use. In Guide to clinical Preventive Service. 2nd ed. Baltimore, MD: Williams & Wilkins 1996:597-609.
  • Daly LE, Mulcahy R., Graham IM, Hickey N. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. BMJ 1983;287:324-6.[Abstract/Free Full Text]
  • Balkau B., Shipley M., Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20 year follow-up in the Whitehall study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-7.[Abstract]
  • UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.[Abstract/Free Full Text]
  • Aspire Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Principal results. Heart 1996;75:334-42.[Abstract/Free Full Text]
  • Pyorala K., Perdersen TR, Kjeksus J. et al. cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian simvastatin study (4S). Diabetes Care 1997;20:614-20.[Abstract]
  • Sacks FM, Pfeffer MA, Moye LA et al. for the cholesterol and recurrent events trial investigators: The effect of Pravastatin on coronary events after myocardial infraction 1 Patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-09.[Abstract/Free Full Text]
  • Long-Term intervention with Pravastatin in Ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and q broad range of initial cholesterol levels: the Long - Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
  • Shepherd J., Macfarlane PW, Blauw GJ et al. on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER) a randomised controlled trial. Lancet 2002;360:1623-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Causes of blindness and partial sight in England and Wales,1990-1991, J Evans, 1995. Office of population Censuses and Surveys, Studies on Medical and Population Subjects, No.57. London: HMSO.
  • Rohan TE, Frost CD, Wald NJ Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. BMJ 1989;299:1198-201.[Abstract/Free Full Text]
  • Young MJ, Breddy JL, Veves A., Boulton AJ The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994;17:557-60.[Abstract]
  • Bild DE, Selby JV, Sinnock P., Browner WS, Braveman P., Showstack JA Lower-extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care 1989;12(1):24-31.[Abstract]
  • Collaborative overview of randomised trials with antiplatelet therapy. Prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ 1994;308: 81-106.[Abstract/Free Full Text]
  • Heart Outcomes Prevention Evaluation (HOPE) study investigators: Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients Randomized to Angiotensin-converting enzyme inhibitor or calcium channel blocker vs Diuretic. JAMA Express 2002;288:2981-94.
  • Lindholm LH, Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mogensen CE, Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependant diabetes. The candesartan and lisinopril microalbuminuria (CALM Study). BMJ 2000;321:1440-4.[Abstract/Free Full Text]
  • New JP, Roxburgh RA, Vaughan NJ, Wallace C., Elliott P., Young RJ Measuring differences in the provision of diabetes care. Diabetes Nutr Metab 2001;14:104-07.[Web of Science][Medline] [Order article via Infotrieve]
  • Gæde P., Vedel P., Larsen N., Jensen GVH, Parving H-H., Pedersen O. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med 2003;348:383-93.[Abstract/Free Full Text]
  • Spooner A., Chapple A., Roland M. What makes British general practitioners take part in a quality improvement scheme? J Health Serv Res Policy 2001;6:145-50.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 6, 410-413 (2003)
DOI: 10.1177/14746514030030060401
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
N. Goenka, S. Thomas, S. Shaikh, J. Morrisey, and V. Patel
Providing diabetes care to Arab migrants in the UK: cultural and clinical aspects
The British Journal of Diabetes & Vascular Disease, November 1, 2007; 7(6): 283 - 286.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
N. Gholap, M. Pillai, S. Virmani, J. D Lee, D. James, J. Morrissey, V. Datta, and V. Patel
The Alphabet Strategy and standards of care in young adults with type 1 diabetes
The British Journal of Diabetes & Vascular Disease, July 1, 2006; 6(4): 168 - 170.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. K Jaiveer, S. Jaiveer, S. B Jujjavarapu, J. Morrissey, J. White, R. Gadsby, and V. Patel
Improvements in clinical diabetes care in the first year of the new General Medical Services contract in the UK
The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 45 - 48.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
V. Patel, O. Pedersen, J. Morrissey, H.-H. Parving, P. Gaede, and J. D. Lee
The `polypill' to reduce cardiovascular risk: proof of concept: Data from the Steno-2 multifactorial intervention study in type 2 diabetes supports the `polypill' strategy to reduce cardiovascular risk
The British Journal of Diabetes & Vascular Disease, September 1, 2004; 4(5): 339 - 341.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jaiveer, P.
Right arrow Articles by Patel, V.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?